PLXNB2 and cancer: Together with the robust antiangiogenic and antiproliferative activities against differentiated bulk cancer cells, ANG-PLXNB2 inhibitors would thus hold promise for the treatment of castration-refractory, drug-resistant, and metastatic prostate cancers.